Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F19%3A00517908" target="_blank" >RIV/68378041:_____/19:00517908 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10394483 RIV/00216208:11140/19:10394483

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1383574219300080?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1383574219300080?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.mrrev.2019.05.002" target="_blank" >10.1016/j.mrrev.2019.05.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review

Popis výsledku v původním jazyce

The development of minimally invasive and low-cost assay enabling early diagnosis, treatment response and prognosis in cancer patients may provide a promising alternative to tumor biopsy. Circulating cell-free DNA (cfDNA) is probably the most promising tool among all components of liquid biopsy. This review includes studies exploring cfDNA as the diagnostic, prognostic or predictive biomarker for all types of cancer. In this article, we systematically reviewed the relevant literature from PubMed about cfDNA. All articles presented higher cfDNA concentration in cancer patients when compared with patients with benign disease or healthy individuals. Most of the articles showed a connection between cfDNA and prognosis. The presence of high cfDNA level in serum or plasma was associated with worse overall patient's survival. This review supports the idea that the cfDNA analysis represents a promising research area and hopefully in the future, could be applied as a new biomarker for cancer detection, prognosis determination and prediction of the response to therapy.

Název v anglickém jazyce

Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review

Popis výsledku anglicky

The development of minimally invasive and low-cost assay enabling early diagnosis, treatment response and prognosis in cancer patients may provide a promising alternative to tumor biopsy. Circulating cell-free DNA (cfDNA) is probably the most promising tool among all components of liquid biopsy. This review includes studies exploring cfDNA as the diagnostic, prognostic or predictive biomarker for all types of cancer. In this article, we systematically reviewed the relevant literature from PubMed about cfDNA. All articles presented higher cfDNA concentration in cancer patients when compared with patients with benign disease or healthy individuals. Most of the articles showed a connection between cfDNA and prognosis. The presence of high cfDNA level in serum or plasma was associated with worse overall patient's survival. This review supports the idea that the cfDNA analysis represents a promising research area and hopefully in the future, could be applied as a new biomarker for cancer detection, prognosis determination and prediction of the response to therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30101 - Human genetics

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mutation Research-Reviews in Mutation Research

ISSN

1383-5742

e-ISSN

—

Svazek periodika

781

Číslo periodika v rámci svazku

jul.-sep.

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

30

Strana od-do

100-129

Kód UT WoS článku

000482872300008

EID výsledku v databázi Scopus

2-s2.0-85065765334